

HARMONY



ALLIANCE

Connect with us at the Annual Congress of the European Hematology Association (EHA2023)


8-11 June 2023 | Messe Frankfurt, Germany

Participate in the HARMONY Alliance session about the impact of Real-World Data and Real-World Evidence on research and clinical care.

Sunday 11 June, 09:45 - 10:45 hrs.

HARMONY Alliance Big Data Platform and data analytic presentations in **booth F117**.

Poster and oral presentations of HARMONY Alliance abstracts in ALL, CLL, MDS and APL.



Big Data innovations in hematologic malignancies: Novel analytic tools and insights

Big Data innovations can support hematologists in selecting the best treatment for patients with hematologic malignancies. The HARMONY Alliance has built a Big Data Platform that facilitates state-of-the-art Big Data research projects in hematologic malignancies.

We invite hematologists to become involved, share data, define research questions and submit research proposals that utilize this infrastructure to improve the treatment of blood cancer.

After more than six years of intensive collaboration, the HARMONY Alliance is now reaping the benefits of the HARMONY Big Data Platform. We developed a range of integrated data services to advance blood cancer research. These data services allow researchers to apply advanced techniques including statistical modelling, Machine Learning, Neural Networks and Deep Learning to the data. As a result, HARMONY data science teams can model complex processes such as disease progression, and they can identify new markers and perform risk stratification.

Through a wide variety of research and multi-stakeholder activities, we have utilized the power of Big Data. Scientists and physicians have teamed up to produce novel insights into the biology of HMs. To detect relevant patterns, they run new algorithms and perform analyses on the thousands of anonymized data sets stored in the HARMONY Big Data Platform. The results may be used to identify high-risk patients with greater reliability and to guide treatment choices in the future.



Overview HARMONY Alliance activities EHA2023

- | | |
|------------------------|---|
| 09 June, 18:00 - 19:00 | Abstract ALL: Poster presentation in Hall 3.0 |
| 09 June, 14:45 - 16:00 | Abstract CLL: Oral presentation in Panorama 1 |
| 10 June, 11:30 - 12:45 | Abstract MDS: Oral presentation in Harmonie 2 |
| 11 June, 09:45 - 10:45 | Session: The impact of Real-World Data and Real-World Evidence on research and clinical care in Hall 3.2. |
| 11 June, 11:30 - 12:45 | Abstract APL: oral presentation in Panorama 2 |



08 – 11 June

Visit us in booth F117 and at the EHA Collaboration Plaza



HARMONY Alliance

ABSTRACTS

09 JUNE 18:00 - 19:00 (Hall 3.0)

Session: Acute lymphoblastic leukemia - Clinical



ALL - Poster (P362): Outcomes in patients with relapsed or refractory acute lymphoblastic leukemia receiving hematopoietic cell transplantation (HSCT) using real-world data from HARMONY.



HARMONY Research Project ALL-4: Harnessing the Power of Big Data to Predict Outcomes Post-Stem Cell Transplant in Adult R/R ALL.



Alexander
Russell-Smith,
Pfizer

09 JUNE 14:45 - 16:00 (Panorama 1)

Session: s411 CLL clinical



CLL - Oral (S149): Other malignancies in the history of CLL: the final analysis of the international multicenter study conducted by ERIC, in HARMONY



HARMONY Research Project CLL-2: Exploring the occurrence of other malignancies in CLL patients using the HARMONY BigData platform



Chatzikonstantinou
Thomas,
ERIC-Certh



BIG DATA FOR BLOOD CANCER

10 JUNE 14:45 - 16:00 (Panorama 1)

Session: s424 Clinical updates in MDS



MDS - Oral (S173): Retrospective study of lenalidomide discontinuation in patients with myelodysplastic syndrome harboring del(5q). A HARMONY study



HARMONY Research Project MDS-2: A retrospective study of patients with Myelodysplastic Syndrome



Elena Crisa,
Candiolo
Cancer
Institute,
FPO-IRCCS

11 JUNE 11:30 - 12:45 (Panorama 2)

Session: s442 AML clinical studies and risk stratification



AML - Oral (S136): Analysis of long-term survival in a large Acute Promyelocytic Leukemia (APL) patient cohort: a Harmony Alliance study



HARMONY Research Project AML-2: Optimizing Acute Promyelocytic Leukemia Management Using Big Data



**Luca
Guarnera,**
PTV-
Policlinico
Tor Vergata di
Roma

Accelerating better and faster
treatment for Blood Cancer Patients

HARMONY Alliance

SESSION: s238

11 JUNE 09:45 - 10:45 in Hall 3.2.

The power of data innovation in hematology



Ignacio Quiles, European Hematology
Association, HARMONY Partner

The power of collaboration: the HARMONY Alliance – the success of 7 years of multi-stakeholder collaboration - Facts & figures



Jesús Maria Hernández Rivas, IBSAL, HARMONY
Alliance Coordinator



Guillermo Sanz,
Hospital La Fe, HARMONY
Alliance Co-Chair

The power of Big Data to improve the treatment of Hematologic Malignancies

Big data, RWD and RWE scientific highlights in:



ALL: Amin Turki,
Universitätsklinikum Essen,
HARMONY Alliance ALL



AML: Marta Sobas,
Medical University of Wrocław,
HARMONY Alliance AML



CML: Andreas Hochhaus,
Friedrich-Schiller-Universität Jena,
HARMONY Alliance CML

Regulatory decision improvement by strengthening the place of data analysis into medicines assessment – including EMA big data activities such as DARWIN



Kelly Plueschke,
European Medicines Agency (EMA)

The impact of Real World Data and Real-World Evidence on research and clinical care now and in the future

Data-driven – RWD & RWE - research in hematology: Values, opportunities and decision making



From the perspective of clinicians: **Kimmo Porkka**,
University of Helsinki, HARMONY Alliance Partner,
EHA Health Data Steering Group



From the perspective of patients: **Natacha Bolaños**,
Lymphoma Coalition, HARMONY Alliance Partner,
HARMONY Alliance Patient Cluster, EHA Patient Advocacy Committee



From the perspective of the pharma industry: **Farzad Ali**,
Pfizer, HARMONY Alliance Partner,
HARMONY Alliance EFPIA Cluster

Introducing the HARMONY Research Foundation

Welcome in our booth!

Big Data has proven to offer new insights that can contribute to advances in novel therapies and more efficient medicines. In our booth HARMONY Alliance data scientists will explain about the data journey and the value of working with the Big Data Platform.

Session participants and EHA2023 conference attendees are invited to visit the **HARMONY Alliance booth F.117** at the EHA2023 exhibition. You can also find us at the **EHA Collaboration Plaza**.

Would you like to book a meeting slot? Please email:
communications@harmony-alliance.eu.

Transforming high quality data into meaningful evidence. Our call to leverage big data!

Let us explore how we can join forces to improve
the lives of people with hematologic malignancies!



www.harmony-alliance.eu

@HARMONYNetEU

#bigdataforbloodcancer



The HARMONY Alliance is a public-private European Network of Excellence for Big Data in Hematology. Our mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more effective treatment strategies.



www.ehaweb.org

@EHA_hematology

#EHA #EHA2023



The HARMONY Alliance consists of two projects funded through the Innovative Medicines Initiative (as of 2022 called IMI, Innovative Health Initiative); HARMONY and HARMONY PLUS. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA)



www.harmony-alliance.eu

